Aim: The aim of our study was to identify pharmacodynamic biomarkers and assess differential effects of tumor necrosis factor (TNF)-and non-TNF-targeting agents on rheumatoid arthritis (RA) patients with an inadequate response to anti-TNF agents (anti-TNF-IR) in comparison with biologic-naïve patients. 
| INTRODUCTION
Treatment of rheumatoid arthritis (RA) patients with anti-tumor necrosis factor (TNF) agents has substantially improved patient outcomes. 1 However, many patients with RA either fail to respond adequately or lose responsiveness to treatment over time. Consortium of Rheumatology Researchers of North America registry analysis shows that around 80% of patients do not achieve remission defined by Clinical Disease Activity Index (CDAI; score ≤2.8) and Disease Activity Score of 28 joints (DAS28; score <2.6) within 1 year of anti-TNF treatment. 2 Treatment options for patients with an inadequate response to anti-TNF agents (anti-TNF-IR) includes switching to an alternative TNF antagonist or switching to a biologic with a different mode of action, such as inhibitors of interleukin-6 (IL-6) receptor, Janus kinase (JAK), B cell-restricted surface antigen CD20, or T cell co-stimulation. 3 Second-line anti-TNF has been associated with lower healthcare costs and resource utilization than switching to a non-TNF agent. 4 Observational studies and meta-analyses provided inconsistent evidence about the comparative effectiveness of different treatment strategies in anti-TNF-IR patients. [5] [6] [7] Recently, a randomized controlled trial demonstrated that a non-TNF-targeted biologics had better efficacy than an alternative TNF inhibitor in anti-TNF-IR patients. 8 However, little is known about the pathophysiologic pathways modified by different biologics in anti-TNF-IR patients compared with biologic-naïve patients, let alone identifying biomarkers to realize the promise of personalized medicine in this population of RA patients.
EARTH EXPLORER 2 (NCT01715896) was a phase IIb trial
designed to compare a TNF antagonist, golimumab, with a non-TNF agent, mavrilimumab, in patients with an inadequate response to a traditional disease-modifying antirheumatic drug (DMARD-IR) and in anti-TNF-IR patients. 9 Mavrilimumab is a fully human monoclonal antibody that inhibits the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor-α. Several clinical trials have demonstrated its clinical efficacy and acceptable safety profile in RA patients. [10] [11] [12] EARTH EXPLORER 2 indicated similar clinical benefit across measures of disease improvement at day 169 for mavrilimumab (100 mg every other week) and golimumab (50 mg every 4 weeks) in patients with a history of anti-TNF-IR. 9 There are other GM-CSF-targeting agents, such as namilumab and GSK3196165, being developed for the treatments of RA, osteoarthritis, and plaque psoriasis. 13 Using samples from the head-to-head EARTH EXPLORER 2 trial,
we assessed peripheral biomarkers and downstream pathways modulated by golimumab and mavrilimumab in both DMARD-IR and anti-TNF-IR patients. To our knowledge, this is the first translational study to evaluate the pharmacodynamic effects of different biologics in anti-TNF-IR patients, which reveals unique biomarker-treatment relationships and provides valuable insights into mechanisms of TNFand non-TNF-targeting biologics in two strata of RA patients. In addition, we examine the association between early biomarker change and late clinical response to anti-TNF therapies, which may provide potential predictive utility for the selection of different treatment regimens in anti-TNF-IR patients.
| MATERIALS AND METHODS

| Clinical samples and study approval
In the phase IIb, exploratory, double-blind, randomized, parallelgroup, multicenter study (EARTH EXPLORER 2), 75 DMARD-IR and 63 anti-TNF-IR patients were randomized in a 1:1 ratio to receive subcutaneous dosages of 100 mg of mavrilimumab every other week (n = 70) or 50 mg of golimumab every other week (n = 68), alternating with placebo, in combination with methotrexate (7.5-25.0 mg/ wk), for 24 weeks. 9 Anti-TNF-IR patients were defined as those with an inadequate response, safety issue or intolerance to one or two anti-TNF agents other than golimumab, given for at least 3 months, with the last dose at least 8 weeks prior to first study dosage. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Guidance for Good Clinical Practice and was approved by the appropriate institutional review boards or independent ethics committees at each site. All patients provided written informed consent.
| Serum proteomics study
Sera 
| Transcriptome study
PAXgene whole blood samples were collected from RA patients and age-, race-, and sex-matched healthy controls to prepare sequencing libraries by total RNA extraction, ribosomal RNA (rRNA) depletion, and stranded library preparation. Whole transcriptome sequencing was then performed using the Illumina HiSeq2500 platform at GeneWiz LLC (South Plainfield, NJ, USA). Paired-end 101 base pair reads were mapped to the GRCh37/hg19 reference genome using Spliced Transcripts Alignment to a Reference (STAR), 14 and the number of reads mapped to each Ensembl gene was calculated by HTSeqcount. 15 For the differential gene expression analysis, we only utilized genes with more than 20 mapped reads across all samples.
Normalized counts of sequence reads mapped to Ensemble genes were compared between baseline and day 169 following administration by
DESeq2. 16 Ingenuity Pathway Analysis was used to identify enriched canonical pathways and upstream transcriptional regulators, which may explain the observed gene expression changes. 17 
| Statistics
We analyzed serum biomarker changes from baseline using a restricted maximum likelihood-based mixed-effects model, including the fixed, categorical effects of treatment, patient subgroup, visit, and subgrouptreatment-visit interaction, as well as the continuous, fixed covariate of baseline score. Patient-level intercept and visit variables were included as random effects. An unstructured variance matrix was used to model the within-patient errors. Significant difference between treatments was tested using least-square mean changes from baseline at each visit.
All analyses were conducted in R using nlme and lsmeans packages. 18 Spearman correlation tests were used to assess the association between biomarker and clinical score changes, and their statistical significance was determined via the asymptotic t approximation.
Simple and multiple linear regression models were fitted using the least-squares approach. The area under the curve (AUC) for the separation of responders and nonresponders was tested by the receiver operating characteristic (ROC) analysis.
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3 | RESULTS
| Differential regulation of serum biomarkers by anti-TNF and anti-GM-CSF receptor agents
We applied a linear mixed-effects model with baseline biomarker level adjustment to investigate post-treatment biomarker changes.
Our results demonstrated a significant difference in golimumab-and mavrilimumab-induced changes of three serum proteins in both DMARD-IR and anti-TNF-IR patients (P < 0.05). The concentrations of CXCL13 were reduced by golimumab but not by mavrilimumab, whereas CCL22 was suppressed by mavrilimumab but not by golimumab in RA patients. Although both treatments reduced CCL17
concentrations, a much larger change was observed after administration of mavrilimumab ( Figure 1 ).
Three-way interactions between treatment effects, patient subgroups, and day 85 or 169 were evident in the mixed-effects models for 6 serum proteins (P < 0.05). Both mavrilimumab and golimumab demonstrated early and sustained suppression of IL-6, CRP, CD163, IL-2RA, VEGF, and MMP1 in DMARD-IR patients. However, golimumab-induced early changes returned toward baseline concentrations, whereas mavrilimumab-elicited suppression was maintained through day 169 for anti-TNF-IR patients (Figure 2 ).
| Gene expression profiles of DMARD-IR and anti-TNF-IR RA patients in comparison with healthy controls
Using RNA-sequencing technology, we compared whole-transcriptome gene expressions among 20 healthy controls, 68 DMARD-IR patients, and 59 anti-TNF-IR patients at baseline. There were no significant differences in age, sex, or race between these three groups.
Interestingly, anti-TNF-IR patients showed significantly greater disease activity scores, including the DAS28-CRP, Health Assessment Questionnaire Disability Index, and swollen joint count, than DMARD-IR patients, whereas concurrent medication profiles were similar between the two groups ( Figure S1 ).
| Differential regulation of gene expression by anti-TNF and anti-GM-CSF receptor agents in DMARD-IR and anti-TNF-IR RA patients
Post-treatment analysis demonstrated significant regulation of 1040 and 2129 transcripts in 36 and 32 DMARD-IR patients at day 169 after administration of mavrilimumab and golimumab, respectively.
The upstream regulator analysis part of the ingenuity pathway analy- 
| Predictive biomarker for anti-TNF antibody in anti-TNF-IR patients
The Spearman correlation analysis demonstrated a significant correlation between day 29 IL-6 suppression and day 169 DAS28-CRP reduction after golimumab treatment in anti-TNF-IR patients 
| DISCUSSION
Our previous study has demonstrated a suppressive effect of GM-CSF blockade on myeloid cells, including reduced macrophagederived CCL22 levels following administration of mavrilimumab.
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CCL17 production was also induced by a GM-CSF-dependent pathway in monocytes/macrophages to mediate inflammation. 23 The current results demonstrate that both CCL22 and CCL17 may serve as specific pharmacodynamic markers for GM-CSF pathway targeting therapies, while CXCL13 was specifically regulated by anti-TNF therapies in RA. CXCL13 is a marker for germinal center activity. 24 Its suppression by golimumab is consistent with the disruptive effects of anti-TNF therapy on lymphoid germinal centers in RA patients. 25 Multiple GM-CSF-targeting agents are being developed for the treatments of different inflammatory disorders. 13 GSK3196165 is a human anti-GM-CSF mAb developed by MorphoSys AG and inlicensed by GlaxoSmithKline. 26 Phase II trials have been commenced to explore the potential of this mAb for the treatments of RA and osteoarthritis. Namilumab is a human immunoglobulin (IgG)1 anti-GM-CSF mAb developed by Takeda, which is being tested in patients with plaque psoriasis and is being compared with anti-TNF F I G U R E 1 Golimumab-and mavrilimumab-specific pharmacodynamic biomarkers in rheumatoid arthritis (RA). A, chemokine (C-C motif) ligand 17 (CCL17) and CCL22 concentrations were reduced by mavrilimumab, whereas B, chemokine CXC ligand 13 (CXCL13) concentrations were suppressed by golimumab in both disease populations. Shown are leastsquare means and associated standard errors in percentage change from baseline for each post-administration visit. Significant differences between golimumab-and mavrilimumab-induced changes were tested separately for disease-modifying antirheumatic drug inadequate response (DMARD-IR) and antitumor necrosis factor inadequate response (anti-TNF-IR) patients. *P < 0.05, **P < 0.01, ** * P < 0.001 Furthermore, a dosage of 150 mg mavrilimumab demonstrated greater efficacy than a dosage of 100 mg in patients with DMARD-IR. 10 It is reasonable to expect that a higher dosage of mavrilimumab over a longer treatment period may demonstrate a better clinical response than an alternative anti-TNF agent in anti-TNF-IR patients.
The increased immune system disruption seems to be a characteristic feature of RA patients who were refractory to anti-TNF treatments. It has been suggested that higher circulating levels of Th17 cells and IL17A may be predictive biomarkers for anti-TNF-IR patients. 28, 29 Neutrophil granule genes exhibited higher expression in nonresponders than in responders before treatment with anti-TNF agents. 30 Monocyte numbers have been reported to be higher in nonresponders than in responders after 3 or 6 months of anti-TNF treatment. 31 These results suggest enhanced activity of alternative immune pathways in anti-TNF-IR patients that may be targeted for clinical improvement.
One reason for the loss of efficacy is immunogenicity, which caused changes in bioavailability and pharmacokinetics. In this case, a second anti-TNF may be as effective as a non-TNF. 32 However, anti-drug antibodies are not detectable in most anti-TNF-IR patients, in whom alternative immune pathways may be particularly active or enhanced by prior treatment with anti-TNF agents to restore clinical activity that was originally modulated by the anti-TNF antibody. Least squares multiple regression was used to assess the contribution of age, sex, baseline IL-6 concentration, baseline DAS28-CRP level, and day 29 IL-6 change to day 169 change in DAS28-CRP score after golimumab treatment in anti-tumor necrosis factor inadequate response patients.
The early IL-6 change was the only significant factor for the prediction of day 169 DAS28-CRP change. DAS28-CRP, Disease Activity Score of 28 joints using C-reactive protein. 
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